Fortis Healthcare receives GST orders totaling ₹2149.61 Lakhs
Fortis Healthcare received GST orders for FY 2020-21, 2021-22, and 2022-23. The total confirmed demand, including interest and penalty, amounts to ₹478.08 lakhs, ₹850.00 lakhs, and ₹811.53 lakhs respectively. Show cause notices for the remaining amounts were dropped.
The confirmed demands, including penalties and interest, represent a significant financial obligation for the company. While not immediately crippling, these amounts could impact profitability and cash flow, thus warranting a medium impact assessment.
The announcement details GST orders received by the company. While there are confirmed demands, the company also had show cause notices for balance amounts dropped. The financial implications are outlined, but without further context on the company's ability to contest or the overall financial health, the sentiment is neutral.
Fortis Healthcare Limited has announced that it is in receipt of Goods and Services Tax (GST) orders for the financial years 2020-21, 2021-22, and 2022-23. The orders pertain to show cause notices issued by the State Tax Officer (ST)- Group IX, Chengalpattu Intelligence Division, Tamil Nadu.
For FY 2020-21, GST authorities have confirmed demands of ₹478.08 lakhs, which includes interest and penalty of ₹142.02 lakhs and ₹168.03 lakhs, respectively. For FY 2021-22, the confirmed demand is ₹850.00 lakhs, including interest and penalty of ₹212.16 lakhs and ₹318.92 lakhs. For FY 2022-23, the confirmed demand stands at ₹811.53 lakhs, with interest and penalty amounting to ₹158.58 lakhs and ₹326.47 lakhs, respectively. The show cause notices related to the balance amounts have been dropped.
The event of receiving these orders occurred on December 29, 2025, at 5:46 PM for FY 2020-21, and at 5:53 PM for FY 2021-22. For FY 2022-23, the order was received on December 30, 2025, at 4:38 PM.
What to do with a filing like this
Fortis Healthcare Limited filed this with the NSE as a statutory disclosure, categorised under litigation updates. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Fortis Healthcare Limited. Read the original for the full detail.